Literature DB >> 2024483

Genetic and molecular biological characterization of a vaccinia virus gene which renders the virus dependent on isatin-beta-thiosemicarbazone (IBT).

R J Meis1, R C Condit.   

Abstract

We have sequenced and analyzed the transcription of a gene capable of rendering vaccinia virus (VV) dependent upon isatin-beta-thiosemicarbazone (IBT) for growth. Marker rescue analysis of an IBT-dependent mutant of VV, IBTd-1, and a temperature-sensitive mutant of VV, ts56, both of which require IBT to grow at 40 degrees, showed that both lesions mapped to gene G2R. VV mutants with G2R deletions were constructed and shown to also be dependent upon IBT for growth. The nucleotide sequence changes responsible for IBTd-1, ts56, and the gene G2R deletion mutants were determined, and taken together show that IBT dependence results from inactivation of the orf G2R gene product. Gene G2R, which has the capacity to encode a 26-kDa protein, is transcribed solely early during infection. The 1.3-kb mRNA contains a 5' untranslated region of almost 600 nucleotides, and terminates about 20 nucleotides downstream from an early transcription termination signal. Transcription analyses of three flanking genes, as well as the map positions of the VV mutants ts11 and ts60 are also presented.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2024483     DOI: 10.1016/0042-6822(91)90585-y

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  17 in total

1.  Cidofovir resistance in vaccinia virus is linked to diminished virulence in mice.

Authors:  Graciela Andrei; Don B Gammon; Pierre Fiten; Erik De Clercq; Ghislain Opdenakker; Robert Snoeck; David H Evans
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

2.  Characterization of a 7-kilodalton subunit of vaccinia virus DNA-dependent RNA polymerase with structural similarities to the smallest subunit of eukaryotic RNA polymerase II.

Authors:  B Y Amegadzie; B Y Ahn; B Moss
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

3.  The envelope G3L protein is essential for entry of vaccinia virus into host cells.

Authors:  Ruzan A Izmailyan; Cheng-Yen Huang; Shamim Mohammad; Stuart N Isaacs; Wen Chang
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

4.  Genetic Confirmation that the H5 Protein Is Required for Vaccinia Virus DNA Replication.

Authors:  Kathleen A Boyle; Matthew D Greseth; Paula Traktman
Journal:  J Virol       Date:  2015-04-08       Impact factor: 5.103

5.  A targeted approach to identification of vaccinia virus postreplicative transcription elongation factors: genetic evidence for a role of the H5R gene in vaccinia transcription.

Authors:  Steven G Cresawn; Richard C Condit
Journal:  Virology       Date:  2007-03-21       Impact factor: 3.616

Review 6.  Orthopoxvirus targets for the development of antiviral therapies.

Authors:  Mark N Prichard; Earl R Kern
Journal:  Curr Drug Targets Infect Disord       Date:  2005-03

7.  Phenotypic characterization of mutants in vaccinia virus gene G2R, a putative transcription elongation factor.

Authors:  E P Black; R C Condit
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

8.  Targeted construction of temperature-sensitive mutations in vaccinia virus by replacing clustered charged residues with alanine.

Authors:  D E Hassett; R C Condit
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

9.  Spontaneous mutations in the human immunodeficiency virus type 1 gag gene that affect viral replication in the presence of cyclosporins.

Authors:  C Aberham; S Weber; W Phares
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

10.  Vaccinia virus temperature-sensitive mutants in the A28 gene produce non-infectious virions that bind to cells but are defective in entry.

Authors:  Peter C Turner; Bradley P Dilling; Cindy Prins; Steven G Cresawn; Richard W Moyer; Richard C Condit
Journal:  Virology       Date:  2007-05-17       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.